Neue Antikoagulantien – Gleichwertig oder wirksamer, gleich oder besser verträglich?

Autor:	Job Harenberg
Rok vydání:	2009
Předmět:	Rivaroxaban medicine.drug_mechanism_of_action Unstable angina business.industry Factor Xa Inhibitor Atrial fibrillation General Medicine medicine.disease Otamixaban Dabigatran Clinical trial chemistry.chemical_compound chemistry Anesthesia medicine Apixaban business medicine.drug
Zdroj:	Der Klinikarzt. 38:443-451
ISSN:	1439-3859 0341-2350
Popis:	Initial clinical trials have shown that new oral anticoagulants yield at least equal or even more effective and at least equally or better tolerated results than INR-adjusted coumarins. So far, data have been published for Dabigatran for atrial fibrillation. Further results for Rivaroxaban and Apixaban for this will be shortly available. Initial data for the systemically applied new anticoagulants show an improved efficacy of the intravenously applied direct factor Xa inhibitor Otamixaban in patients with unstable angina pectoris. The very long-acting subcutaneously administered Idrabiotaparinux is being tried out on pulmonary embolism patients. The neutralisation of the anticoagulant effect and the elimination of the substance by means of intravenously administered Avidin (an ovalbumin) are important.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::061b44475044636a91d2de21213344ce https://doi.org/10.1055/s-0029-1243265 Zobrazit plný text záznamu